Three monoclonal antibodies that target PD-L1 (atezolizumab, durvalumab, and avelumab) are approved for clinical use, including for non-small cell lung cancer (Ramamurthy et al., 2024). This evidence concerns the gene CD274 and non-small cell lung carcinoma.